To aid in planning bioresearch monitoring (BIMO) inspections, the FDA Center for Drug Evaluation and Research issued draft guidance stipulating the standardized format for electronic submission of major studies for new drug applications (NDAs) and biologics license applications (BLAs) regulated by the Center. Two years after the draft guidance is made final, the FDA will requ... Read More